Streetbeat News

Products Services

IRWD

Ironwood Pharmaceuticals has revised its FY 2024 financial guidance due to continued pricing pressure on Linzess, driven by higher-than-expected Medicaid utilization trends. The company now expects sales of $350M-$375M, down from the prior range of $405M-$425M and below the consensus of $410.05M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:08 am

MSFT

PLTR

Palantir shares are trading higher following the announcement of a partnership with Microsoft to enhance analytics and AI services for classified networks.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:02 am

MSFT

PLTR

Palantir and Microsoft are advancing their partnership to offer advanced cloud, AI, and analytics capabilities to the U.S. defense and intelligence community. This includes integrating Microsoft's Azure OpenAI Service within Palantir's AI platform.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:59 am

F

Ford Motor Co (NYSE:F) has introduced higher-end variants of the 2025 Ford Maverick truck after witnessing an 80% increase in sales for the model in 2024 through July. The new variants, Tremor and Lobo, are priced at $39,795 and $40,495 respectively, with orders starting on August 1 and deliveries set for early 2025.

Portfolio Pulse from Anan Ashraf

August 08, 2024 | 10:56 am

LLY

Eli Lilly has raised its 2024 full-year revenue guidance by $3 billion to a range of $45.4 billion to $46.6 billion, driven by strong performance of Mounjaro and Zepbound, as well as non-incretin medicines. The company has also improved clarity on production expansions and planned Mounjaro launches outside the U.S.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:49 am

MRK

Merck has announced the discontinuation of its Phase 3 KeyVibe-008 trial based on the recommendation of an independent data monitoring committee. The trial did not meet the primary endpoint of overall survival and showed higher rates of adverse events in the treatment arm.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:47 am

BIVI

BioVie shares are trading higher after the company achieved alignment with the FDA on its upcoming SUNRISE-PD trial in Parkinson's disease. The company is conducting trial start-up activities with plans to initiate patient screening in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:15 am

BIVI

BioVie has aligned with the FDA on its upcoming SUNRISE-PD trial for Parkinson's disease, focusing on the effects of bezisterim (NE3107) on motor and non-motor symptoms in approximately 60 patients. The company plans to start patient screening in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:09 am

BEEM

Beam Global has signed its first distribution agreement for the European market with Geci Group. Geci Group will market, sell, service, and support Beam Global products in Spain, Portugal, and the Spanish-speaking Caribbean.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:07 am

VTNR

Vertex Energy has released its Q3 2024 outlook, projecting capital expenditures between $15M-$20M and direct operating expenses per barrel between $5.52-$6.02. The Mobile Refinery's conventional throughput volume is expected to be between 55.0 Mbpd and 60.0 Mbpd, with a capacity utilization of 73%-80%. The production yield profile includes 64%-68% finished products and 32%-36% intermediate and other products.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:06 am